Pembrolizumab‐Induced Morphea in a Patient With Metastatic Urothelial Carcinoma
Case Reports in Urology · 2026-01 · 2026 (1)
DOI: 10.1155/criu/2930700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Urology, online erschienen am 22.07.2026. Verfasst von Matthew A Drescher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Tech Carilion School of Medicine, Virginia Polytechnic Institute and State University, Roanoke, Virginia, USA, vt.edu. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Immune checkpoint inhibitors, such as pembrolizumab, are increasingly used in high‐grade urothelial carcinomas. Immune checkpoint inhibitors are known to cause immune‐related adverse events (irAEs), often involving the skin. Case Presentation Reported is a 59‐year‐old woman with metastatic high‐grade urothelial carcinoma of the right renal pelvis previously treated with chemoradiation and surgery. She developed morphea 1.5 years after initiating pembrolizumab therapy. The patient presented with violaceous, indurated plaques and paresthesias of the lower extremities. Biopsies revealed thickened collagen bundles and perivascular inflammation. MRI excluded eosinophilic fasciitis. She was diagnosed with pembrolizumab‐induced morphea and treated with methotrexate and topical corticosteroids, leading to partial improvement.
Conclusion
As immunotherapy becomes more widely used in urologic oncology, recognition of rare cutaneous irAEs such as morphea is crucial for timely diagnosis and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virginia Tech Carilion School of Medicine, Virginia Polytechnic Institute and State University, Roanoke, Virginia, USA, vt.edu.
- Division of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Virginia Polytechnic Institute and State University, Roanoke, Virginia, USA, vt.edu.
- Dominion Pathology Associates, Roanoke, Virginia, USA.
- Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Virginia Polytechnic Institute and State University, Roanoke, Virginia, USA, vt.edu.
ORCID-Profile: Douglas J Grider
Zitieren
APA
Drescher, M. A., Murray, D. W., & Grider, D. J. (2026). Pembrolizumab‐Induced Morphea in a Patient With Metastatic Urothelial Carcinoma. Case Reports in Urology, 2026(1). https://doi.org/10.1155/criu/2930700
Vancouver
Drescher MA, Murray DW, Grider DJ. Pembrolizumab‐Induced Morphea in a Patient With Metastatic Urothelial Carcinoma. Case Reports in Urology. 2026;2026(1). doi:10.1155/criu/2930700
BibTeX
@article{Drescher2026,
author = {Drescher, Matthew A and Murray, Douglas W and Grider, Douglas J},
title = {Pembrolizumab‐Induced Morphea in a Patient With Metastatic Urothelial Carcinoma},
journal = {Case Reports in Urology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/criu/2930700}
}
EUVIMED